NCT01659255View on ClinicalTrials.gov

Study to Evaluate the Safety and Tolerability of Tirabrutinib (ONO/GS-4059) Given as Monotherapy in Participants With Relapsed/Refractory NHL and CLL

PHASE1CompletedINTERVENTIONAL
Enrollment

90

Participants

Timeline

Start Date

August 17, 2012

Primary Completion Date

February 23, 2015

Study Completion Date

January 11, 2016

Conditions
Non Hodgkins LymphomaChronic Lymphocytic Leukaemia
Interventions
DRUG

Tirabrutinib

Capsules administered orally

Trial Locations (6)

34295

CHU St Eloi, Montpellier

59037

CHRU - Hopital Claude HURIEZ, Lille

69495

Centre hospitalier Lyon Sud, Lyon

CF14 4XW

University Hospital of Wales, Cardiff

LE1 5WW

Leicester Royal Infirmary, Leicester

PL6 8DH

Derriford Hospital, Plymouth

Sponsors

Lead Sponsor

Gilead Sciences
All Listed Sponsors
collaborator

Ono Pharmaceutical Co. Ltd

INDUSTRY

lead

Gilead Sciences

INDUSTRY

NCT01659255 - Study to Evaluate the Safety and Tolerability of Tirabrutinib (ONO/GS-4059) Given as Monotherapy in Participants With Relapsed/Refractory NHL and CLL | Biotech Hunter | Biotech Hunter